1137867-66-3Relevant articles and documents
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Nie, Zhe,Feher, Victoria,Natala, Srinivasa,McBride, Christopher,Kiryanov, Andre,Jones, Benjamin,Lam, Betty,Liu, Yan,Kaldor, Stephen,Stafford, Jeffrey,Hikami, Kouki,Uchiyama, Noriko,Kawamoto, Tomohiro,Hikichi, Yuichi,Matsumoto, Shin-Ichi,Amano, Nobuyuki,Zhang, Lilly,Hosfield, David,Skene, Robert,Zou, Hua,Cao, Xiaodong,Ichikawa, Takashi
, p. 3662 - 3666 (2013/07/05)
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with
HALO-SUBSTITUTED PYRIMIDODIAZEPINES
-
Page/Page column 67-68, (2009/12/28)
The present invention provides PLK1 inhibitor compounds of formula I: useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas. Also provided are intermediate compounds useful in the synthesis of compounds of formula I.